IL315894A - 5-METHOXY-N,N-DIMETHYLTRYPTAMINE for the treatment of postpartum depression - Google Patents

5-METHOXY-N,N-DIMETHYLTRYPTAMINE for the treatment of postpartum depression

Info

Publication number
IL315894A
IL315894A IL315894A IL31589424A IL315894A IL 315894 A IL315894 A IL 315894A IL 315894 A IL315894 A IL 315894A IL 31589424 A IL31589424 A IL 31589424A IL 315894 A IL315894 A IL 315894A
Authority
IL
Israel
Prior art keywords
dimethyltryptamine
methoxy
treatment
postpartum depression
postpartum
Prior art date
Application number
IL315894A
Other languages
English (en)
Hebrew (he)
Inventor
Theis Terwey
Conor Burke
Naoise Gaffney
Original Assignee
Gh Res Ireland Limited
Theis Terwey
Conor Burke
Naoise Gaffney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited, Theis Terwey, Conor Burke, Naoise Gaffney filed Critical Gh Res Ireland Limited
Priority claimed from PCT/EP2023/057874 external-priority patent/WO2023186827A1/en
Publication of IL315894A publication Critical patent/IL315894A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL315894A 2022-03-27 2023-03-27 5-METHOXY-N,N-DIMETHYLTRYPTAMINE for the treatment of postpartum depression IL315894A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22000085 2022-03-27
EP22000084 2022-03-27
EP23153996 2023-01-30
EP23154014 2023-01-30
PCT/EP2023/057874 WO2023186827A1 (en) 2022-03-27 2023-03-27 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression

Publications (1)

Publication Number Publication Date
IL315894A true IL315894A (en) 2024-11-01

Family

ID=93292078

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315894A IL315894A (en) 2022-03-27 2023-03-27 5-METHOXY-N,N-DIMETHYLTRYPTAMINE for the treatment of postpartum depression

Country Status (8)

Country Link
US (1) US20250205200A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499080A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510915A (cg-RX-API-DMAC7.html)
KR (1) KR20240167886A (cg-RX-API-DMAC7.html)
CN (1) CN119156213A (cg-RX-API-DMAC7.html)
AU (1) AU2023242438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255671A1 (cg-RX-API-DMAC7.html)
IL (1) IL315894A (cg-RX-API-DMAC7.html)

Also Published As

Publication number Publication date
AU2023242438A1 (en) 2024-11-07
EP4499080A1 (en) 2025-02-05
JP2025510915A (ja) 2025-04-15
KR20240167886A (ko) 2024-11-28
US20250205200A1 (en) 2025-06-26
CN119156213A (zh) 2024-12-17
CA3255671A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
IL285537A (en) 5-Methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in the treatment of depression
IL315902A (en) 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation
IL315905A (en) 5-METHOXY-N.N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation
IL285539A (en) Preparations containing 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in the treatment of mental disorders
SI3658140T1 (sl) Kombinacije aprocitentana z nadaljnjimi učinkovinami za zdravljenje rezistentne hipertenzije
GB202308830D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
MX2025008755A (es) 5-metoxi-n,n-dimetiltriptamina para el tratamiento de la depresion postparto
CA3281369A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
GB201908902D0 (en) Plasma treatment
GB202316902D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
GB202315176D0 (en) 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) formulations
GB202314993D0 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
CA3295590A1 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
AU2023902197A0 (en) Treatment for tinnitus
GB202505025D0 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
GB202109590D0 (en) Combination treatment for coronavirus
HK40110354A (en) 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
MA39901A (fr) Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles